Gelteq to Present at Investor Summit Virtual on December 9, 2025
Gelteq (Nasdaq: GELS) announced that CEO Nathan Givoni will present at the Q4 Investor Summit Virtual on December 9, 2025 at 4:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Gelteq (Nasdaq: GELS) announced that CEO Nathan Givoni will present at the Q4 Investor Summit Virtual on December 9, 2025 at 4:00 PM ET.
Mr. Givoni will discuss growth strategy, market positioning, and upcoming catalysts. He will also host one-on-one meetings with institutional and high-net-worth investors on December 10, 2025. Investors can request meeting access through the summit registration link or by contacting the conference or Gelteq investor relations at mkreps@darrowir.com. Event contact is fred@investorsummitgroup.com.
Details
News Market Reaction – GELS
On Dec 2, the day this news came out, GELS closed 3.85% above the previous close.
Data tracked by StockTitan Argus for the Dec 2 session.
Key Figures
- Presentation date
- December 9, 2025
- Q4 Investor Summit Virtual
- Presentation time
- 4:00 PM ET
- CEO Investor Summit session
- 1:1 meetings date
- December 10, 2025
- Institutional and HNW investor meetings
Historical Context
-
Three-year China distribution deal with minimum revenue expectations.
-
Preclinical data showing large bioavailability and absorption improvements.
-
CEO presenting growth strategy and catalysts at Q4 Investor Summit.
-
Positive PK data with higher exposure and Cmax versus antihistamine.
-
Launch of preclinical animal trial for oily and poorly soluble drugs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
microcap financial
high net worth financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) (“Gelteq”) today announced that Nathan Givoni, its Chief Executive Officer, will present at the Q4 Investor Summit Virtual on December 9, 2025, where he will share updates on Gelteq’s growth strategy, market positioning, and upcoming catalysts. The Investor Summit is an exclusive virtual event connecting investors with disruptive small and microcap companies. This quarter’s event highlights MicroCap companies with compelling value propositions and near-term growth drivers, offering investors a focused platform for discovery.
Mr. Givoni will be presenting on December 9 at 4:00 PM ET, together with hosting one-on-one meetings with Institutional and High Net Worth (HNW) investors on December 10th. To request a one-on-one meeting, please reach out to the conference contact or Gelteq investor relations, mkreps@darrowir.com.
Event Details:
- Event: Q4 Investor Summit
- Presentation Date & Time: December 9 | 4:00 PM ET
- Request Access: https://investorsummitgroup.com/
- Conference Contact: For more information, please contact: fred@investorsummitgroup.com
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing.
For more information, visit www.gelteq.com.
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.